In stable CAD patients undergoing percutaneous coronary intervention, the administration of omega-3 PUFA (1 g/day) for 4 weeks decreased Lp-PLA2 mass and activity compared to the control (soybean oil capsules) [40]. The gene discussed is PLA2G7; the disease is coronary artery disorder.